Heparin and vasoactive peptides in hemodialysis patients.
Plasma concentrations of vasoactive peptides have been reported to be influenced by various procedural features of hemodialysis (HD), such as ultrafiltration and isovolemic diffusion, dialysate buffer and dialysate temperature, but also by sham HD thus reflecting an effect of the extracorporeal circulation per se. In the present study the effect of heparin administration was investigated in 9 stable HD patients, and compared with that of saline. Blood samples were taken from the arteriovenous fistula before and 45 min after the administration of heparin or saline. After an interval of 2 weeks, the procedure was repeated with the exception that the patients who received heparin on the first occasion were given saline and vice versa. Plasma concentrations of the vasoactive peptides were measured by radioimmunoassay. Regardless of whether heparin was given or not, the plasma concentrations of the vasodilators atrial natriuretic peptide, beta-endorphin and vasoactive intestinal peptide did not change, nor did the concentration of the vasoconstrictor neuropeptide Y. The plasma motilin concentration decreased significantly when heparin was given, and that of substance P increased, both these peptides being vasodilators. Mean arterial blood pressure decreased regardless of whether heparin was given or not, and no difference between the two regimens was noted. Heart rate was unchanged with both regimens. To sum up, administration of heparin but not of saline affected the plasma concentrations of motilin and substance P. However, the decrease in blood pressure during the procedure seemed not to be related to the changes in these peptides, as it also occurred in the absence of heparin.
Hegbrant
J
J
Gambro Group Renal Care, Lund, Sweden. jorgen.hegbrant@gambro.se
Ekman
R
R
Thysell
H
H
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects*; D009320:Atrial Natriuretic Factor / Q000097:blood; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009037:Motilin / Q000097:blood*; D009478:Neuropeptide Y / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects*; D013373:Substance P / Q000097:blood*; D014660:Vasoactive Intestinal Peptide / Q000097:blood; D001615:beta-Endorphin / Q000097:blood
D000925:Anticoagulants; D009478:Neuropeptide Y; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; D009037:Motilin; D001615:beta-Endorphin; D009320:Atrial Natriuretic Factor; D006493:Heparin